Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

Hypertrophic cardiomyopathy (HCM) is a disease characterized by the thickening of the myocardium, leading to left ventricular hypertrophy. HCM commonly has a genetic underpinning and is often associated with mutations in sarcomere genes. It can be asymptomatic, but common symptoms include fatigue, dyspnea, and chest pain. The treatment of HCM typically includes surgery and therapies such as beta blockers and calcium channel blockers. However, the introduction of the first targeted therapy, mavacamten (Bristol Myers Squibb’s Camzyos), marks a significant advance in the management of obstructive HCM—the most common type of HCM—by offering a novel, more-efficacious treatment and a non-invasive alternative to surgery. This advance not only enhances the efficacy of treatment but also significantly improves HCM patients’ quality of life. This analysis of patient-level claims data explores the current pharmacological treatment of HCM in the United States.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HCM patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HCM patients?
• How has Camzyos been integrated into the treatment algorithm, and what is its source of business?
• What percentage of HCM patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of HCM patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Camzyos, diltiazem, metoprolol succinate, verapamil

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.